Clinical Trial

Tocilizumab in Lung Transplantation

Study acronym: ALL IN LUNG
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is a trial in which 350 primary lung transplant recipients will be randomized (1:1) to receive either Tocilizumab (six doses over 20 weeks) plus standard triple maintenance immunosuppression or placebo (sterile normal saline) plus standard triple maintenance immunosuppression (Tacrolimus, Mycophenolate Mofetil, corticosteroids). The primary objective is to test the hypothesis that treatment with triple maintenance immunosuppression plus Tocilizumab (TCZ) is superior to triple maintenance immunosuppression plus placebo (saline) as defined by a composite endpoint of a) CLAD, b) listed for re-transplantation, and c) death
Protocol Amendment History 29 amendments
This ClinicalTrials.gov record has been amended 29 times since 2023-09-08; most recent amendment 2026-06-12.
Status change: Not Yet Recruiting → Recruiting 2023-12-19
Trial Details
NCT Number NCT06033196
Lead Sponsor National Institute of Allergy and Infectious Diseases (NIAID)
Conditions Lung Transplant
Enrollment 350 participants
Start Date 2024-02-13
Primary Completion 2029-01-08 (estimated)
Study Completion 2029-01-08 (estimated)
Updated on ClinicalTrials.gov 2026-08-10